Dr. Johnson and Dr. Bahçe-Altuntaş reply

We appreciate the interest in our editorial1 regarding Dr. Stamp’s study of joint replacement rates in New Zealand2, as expressed by Dr. Boers3. We are happy to have opened an international dialogue regarding barriers to access to biologic disease-modifying antirheumatic drugs (bDMARD). We agree with Dr. Boers that the high price of bDMARD is a … Address correspondence to Dr. B.K. Johnson, Jacobi/NCB, Rheumatology, 1400 Pelham Parkway, South Building 1, Suite 306, New York, New York 10461, USA. E-mail: beverly.johnson06{at}gmail.com